Accelerator Nordic AB holds an active majority position in a number of companies within Bio Pharma and Medical technology
The Accelerator Group is addressing therapeutics and imaging in large growth markets such as oncology, cardiology and drug delivery for orthopedic and dental implants.
Andreas Bunge, CEO at Accelerator presented the company at Avanza/Redeye Financial Hearing on May 20, 2010.
24 June, 2010
PledPharma reports positive results from cancer study
26 April, 2010
SyntheticMR sells first software to Bern
11 March, 2010
Accelerator recruits key personnel
May 1-7, 2010
SyntheticMR at ISMRM in Stockholm
August 27, 2010
Quarterly report January-June
Accelerator Nordic AB is a group of developing companies based on Scandinavian Life Science. The company holds an active majority position in a number of companies within Bio Pharma and Medical technology.
The business model is centered on partnering or out-licensing. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm.
24 June, 2010
© 2010 Accelerator Nordic AB. Alla rättigheter förbehålles.
